Biotech Values

[mcbio]

TEVA—(-16%)—multi-decade low on weak quarter/newly slashed guidance

At what point, if any, does TEVA merit long consideration? Have never followed closely as the market cap has always been too big for me to follow closely. But, looks like current dividend yield is over 8%. I'm sure there is pressure to cut the dividend to some degree going forward but still have to wonder at what point shares would start to look attractive. Is it going to take clear innovation in the pipeline outside of the generics business to engineer a turnaround?